title: IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. December 5-9, 2010, San Diego, CA USA.
abstract: The 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics international conferences, and the 2010 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, were held December 5-9, 2010 in San Diego, CA. The conferences were organized with a focus on antibody engineering only on the first day and a joint engineering/therapeutics session on the last day. Delegates could select from presentations that occurred in two simultaneous sessions on days 2 and 3. Day 1 included presentations on neutralizing antibodies and the identification of vaccine targets, as well as a historical overview of 20 years of phage display utilization. Topics presented in the Antibody Engineering sessions on day 2 and 3 included antibody biosynthesis, structure and stability; antibodies in a complex environment; antibody half-life; and targeted nanoparticle therapeutics. In the Antibody Therapeutics sessions on days 2 and 3, preclinical and early stage development and clinical updates of antibody therapeutics, including TRX518, SYM004, MM111, PRO140, CVX-241, ASG-5ME, U3-1287 (AMG888), R1507 and trastuzumab emtansine, were discussed, and perspectives were provided on the development of biosimilar and biobetter antibodies, including coverage of regulatory and intellectual property issues. The joint engineering/therapeutics session on the last day focused on bispecific and next-generation antibodies.
authors.affiliation: Department of Immunology & Microbial Science, The Scripps Research Institute, La Jolla, USA.
authors.forename: Samantha O
authors.initials: SO
authors.lastname: Arnett
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Teillaud
authors.forename: Theirry
authors.initials: T
authors.lastname: Wurch
authors.forename: Janice M
authors.initials: JM
authors.lastname: Reichert
authors.forename: Cameron
authors.initials: C
authors.lastname: Dunlop
authors.forename: Michael
authors.initials: M
authors.lastname: Huber
mesh_terms: D000818:Animals; D000906:Antibodies / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D001688:Biological Products / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D038622:Internationality; D051379:Mice; D019151:Peptide Library; D015202:Protein Engineering / Q000379:methods / Q000639:trends; D012955:Societies, Medical; D013810:Therapeutic Equivalency; D014481:United States
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D001688:Biological Products; D019151:Peptide Library